Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Next steps in designing for diffusion of pre-exposure prophylaxis: demonstration projects.

Dearing JW, Norton WE, Larson RS.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S156-60. doi: 10.1016/j.amepre.2012.09.028. Review. No abstract available.

PMID:
23253759
2.

Pre-exposure prophylaxis for HIV: can it be implemented in the real world?

Katz MH.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S161-2. doi: 10.1016/j.amepre.2012.10.004. No abstract available.

PMID:
23253760
3.

Providing HIV pre-exposure prophylaxis: lessons learned from the Ryan White HIV/AIDS Program.

Trent-Adams S, Cheever LW.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S147-50. doi: 10.1016/j.amepre.2012.09.031. Review. No abstract available.

PMID:
23253757
4.

HIV pre-exposure prophylaxis diffusion and implementation issues in nonclinical settings.

Hosek SG.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S129-32. doi: 10.1016/j.amepre.2012.09.032. Review. No abstract available.

PMID:
23253753
5.

From efficacy to impact: an advocate's agenda for HIV pre-exposure prophylaxis implementation.

Warren MJ, Bass ES.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S167-70. doi: 10.1016/j.amepre.2012.10.006. No abstract available.

PMID:
23253762
6.

Pre-exposure prophylaxis for HIV: who will benefit and what are the challenges?

Curran JW, Crosby RA.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S163-6. doi: 10.1016/j.amepre.2012.10.005. No abstract available.

PMID:
23253761
7.

A proposed framework to monitor daily oral antiretroviral pre-exposure prophylaxis in the U.S.

Smith DK, Beltrami J.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S141-6. doi: 10.1016/j.amepre.2012.09.040. Review. No abstract available.

PMID:
23253756
8.

Designing for diffusion of a biomedical intervention.

Dearing JW, Smith DK, Larson RS, Estabrooks CA.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S70-6. doi: 10.1016/j.amepre.2012.09.038. Review. No abstract available.

PMID:
23253765
9.

Preparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxis.

Cohen SE, Liu AY, Bernstein KT, Philip S.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S80-5. doi: 10.1016/j.amepre.2012.09.036. Review. No abstract available.

10.

Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.

Edelman EJ, Fiellin DA.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S86-90. doi: 10.1016/j.amepre.2012.09.035. Review. No abstract available.

11.

Introducing wicked issues for HIV pre-exposure prophylaxis implementation in the U.S.

Smith DK, Dearing JW, Sanchez T, Goldschmidt RH.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S59-62. doi: 10.1016/j.amepre.2012.09.057. No abstract available.

PMID:
23253763
12.

Applying chronic illness care, implementation science, and self-management support to HIV.

Elzarrad MK, Eckstein ET, Glasgow RE.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S99-107. doi: 10.1016/j.amepre.2012.09.046. Review. No abstract available.

PMID:
23253770
13.

Primary care and public health partnerships for implementing pre-exposure prophylaxis.

Norton WE, Larson RS, Dearing JW.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S77-9. doi: 10.1016/j.amepre.2012.09.037. Review. No abstract available.

PMID:
23253766
14.

Social justice, public health ethics, and the use of HIV pre-exposure prophylaxis.

Philpott S.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S137-40. doi: 10.1016/j.amepre.2012.09.029. Review. No abstract available.

PMID:
23253755
15.

Adherence to antiretroviral medications for HIV pre-exposure prophylaxis: lessons learned from trials and treatment studies.

Koenig LJ, Lyles C, Smith DK.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S91-8. doi: 10.1016/j.amepre.2012.09.047. Review. No abstract available.

PMID:
23253769
16.

Financial policy issues for HIV pre-exposure prophylaxis: cost and access to insurance.

Horberg M, Raymond B.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S125-8. doi: 10.1016/j.amepre.2012.09.039. Review. No abstract available.

PMID:
23253752
17.

Provider-initiated HIV-risk behavior counseling in the context of HIV pre-exposure prophylaxis.

Thrun MW.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S108-11. doi: 10.1016/j.amepre.2012.09.034. Review. No abstract available.

PMID:
23253749
18.

Brief risk-reduction counseling in clinical settings for HIV pre-exposure prophylaxis.

Malotte CK.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S112-8. doi: 10.1016/j.amepre.2012.09.033. Review. No abstract available.

PMID:
23253750
19.

Using registries to monitor HIV pre-exposure prophylaxis safety in clinical settings.

Tilson HH.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S151-5. doi: 10.1016/j.amepre.2012.09.042. Review. No abstract available.

PMID:
23253758
20.

Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV.

Campbell JD, Herbst JH, Koppenhaver RT, Smith DK.

Am J Prev Med. 2013 Jan;44(1 Suppl 2):S63-9. doi: 10.1016/j.amepre.2012.09.045. Review.

PMID:
23253764

Supplemental Content

Support Center